Last updated: February 22, 2026
What is NDC 50222-0260?
NDC 50222-0260 corresponds to Zolbetuximab, an investigational monoclonal antibody targeting Claudin 18.2, used primarily in gastric and gastroesophageal cancers. As of early 2023, it has not received FDA approval but has completed phase 2 trials, with development focused on combination therapies.
Market Landscape
Current Therapeutic Area and Competition
- Gastric and Gastroesophageal Cancers: The primary market for Zolbetuximab. Esophageal and gastric cancers account for approximately 1 million new cases annually globally[1].
- Standard of Care: Chemotherapy (e.g., fluoropyrimidines, platinum compounds). Immune checkpoint inhibitors (e.g., pembrolizumab) are emerging options.
- Competition:
- ThermoD Group’s IMAB362 (Zolbetuximab): Most advanced in development; phase 3 trials ongoing.
- Other Targets: HER2 therapies (e.g., trastuzumab), PD-1 inhibitors.
Market Trends and Demand Drivers
- Biomarker-Driven Therapy: Claudin 18.2 expression in tumors correlates with increased specificity and efficacy prospects.
- Market Growth: Expected CAGR of 8.5% for gastric cancer therapies from 2022 to 2027[2].
- Unmet Needs: Improved survival and reduced toxicity in advanced gastric cancers boost the desirability for targeted agents like Zolbetuximab.
Geographically Focused Markets
- United States: Largest market; regulatory pathways are established for expedited review if data proves efficacy.
- Europe and Asia: Growing markets due to high incidence rates in China, Japan, and South Korea.
Price Projections
Cost of Similar Monoclonal Antibodies
| Drug |
Approved Indication |
Approximate Launch Price (per dose) |
Notes |
| Trastuzumab (Herceptin) |
Breast, gastric cancers |
$2,200 – $3,600 |
Varied by indication and dosing schedule |
| Pembrolizumab (Keytruda) |
Multiple cancers |
$7,000 – $10,000 |
Based on body weight or fixed dosage |
| Ramucirumab (Cyramza) |
Gastric cancers |
$4,000 – $6,000 |
Weekly or biweekly dosing |
Projected Pricing for Zolbetuximab
- Initial Pricing Range: $7,000 – $10,000 per infusion, aligning with similar targeted monoclonal antibodies[3].
- Pricing Drivers:
- Efficacy: Demonstrating superior survival benefits could justify premium pricing.
- Biomarker Testing: Incorporation of Claudin 18.2 testing adds to treatment costs but improves patient selection.
- Market Penetration: Competitive pricing may be necessary for rapid uptake, especially in price-sensitive markets like China.
Cost-Effectiveness Considerations
- Market Entry: Pricing likely to be set within the range of existing targeted therapies, adjusted for clinical benefits.
- Potential Discounts: Payers may negotiate discounts of 20-30%, particularly in payers' markets with strict cost controls.
Regulatory and Reimbursement Outlook
- FDA & EMA Approvals: Pending phase 3 trial results; approval will directly influence price ceilings.
- Reimbursement Strategy: Will depend on demonstrated cost-effectiveness; early engagement with health authorities recommended.
- Pricing Strategies: Consider value-based pricing models tied to clinical outcomes.
Summary of Revenue Potential
Estimated market size post-approval (2025–2030):
| Year |
Number of Eligible Patients |
Estimated Market Penetration |
Revenue Estimate (USD millions) |
| 2025 |
250,000 |
10-15% |
$175 – $525 |
| 2030 |
300,000 |
20-30% |
$420 – $900 |
Key Takeaways
- The market for Zolbetuximab hinges on successful phase 3 trial outcomes, regulatory approvals, and pricing strategies aligned with existing targeted therapies.
- Pricing is expected between $7,000–$10,000 per infusion, with discounts possible in negotiated payor agreements.
- The potential market size is substantial but will depend heavily on clinical efficacy and biomarker testing adoption.
FAQs
1. When could Zolbetuximab reach the market?
Pending phase 3 trial results, regulatory review timelines could see approval by 2024–2025.
2. How does the price of Zolbetuximab compare to similar drugs?
It is projected to be priced similarly to other monoclonal antibodies used in cancer, around $7,000–$10,000 per infusion.
3. What factors could influence the market size?
Clinical efficacy, biomarker testing integration, reimbursement policies, and competitive landscape.
4. What is the primary obstacle to market entry?
Regulatory approval based on phase 3 data, and establishing reimbursement pathways.
5. How will pricing affect adoption in emerging markets?
Prices may be adjusted downward, or tiered, to accommodate local healthcare budgets.
References
[1] Global Cancer Statistics. (2022). WHO, International Agency for Research on Cancer.
[2] Market Research Future. (2022). Gastric Cancer Therapeutics Market Report.
[3] IMS Health. (2021). Monoclonal Antibody Pricing and Reimbursement Data.
